P-681. Evaluation of Clinical Characteristics and Antimicrobial Stewardship Interventions in Mycoplasma pneumoniae Infections at a Community Teaching Hospital

Abstract Background Patients admitted with community-acquired pneumonia (CAP) are empirically treated with broad-spectrum antibiotics due to challenges identifying causative organisms. Mycoplasma pneumoniae is a common atypical pathogen but has historically been difficult to detect. Implementation of rapid molecular diagnostics at our institution improved detection of M. pneumoniae, supporting more targeted interventions by the Antimicrobial Stewardship Program (ASP). A recent rise in M. pneumoniae cases presented an opportunity to assess clinical characteristics, management, and stewardship impact. Methods We performed a retrospective review of patients admitted to our institution from June 2024 – March 2025 with M. pneumoniae identified by PCR, including the Respiratory Pathogen Panel (RPP) and the Pneumonia Panel (PN). Data collected included demographics, comorbidities, imaging, co-infections, antimicrobial therapy, ASP interventions, and outcomes. Results 55 patients were reviewed (median age 46 years, 60% female), with most diagnoses occurring in fall months (September–November). Dyspnea and cough were the most common complaints. Pneumonia was diagnosed in 76% of cases and 19% of those were admitted to the ICU. Potential co-pathogens were observed in 44%, including bacterial (14%), viral (16%), and mixed (13%) cases. Median length of stay was 3 days; mortality was 5.5%. Most patients received azithromycin (47%) or doxycycline (45%). The ASP provided 53 interventions across 29 patients, including 7 in which atypical coverage was initiated. Median procalcitonin and WBC were 0.13 and 10, respectively. Additional results in Tables 1–3. Conclusion A marked rise in M. pneumoniae cases was observed over the review timeframe, consistent with known cyclical trends and potentially influenced by reduced public health mitigation measures following the COVID-19 pandemic. Most infections occurred in younger female patients with typical clinical findings and were managed on general medical floors with short stays. Rapid diagnostic testing facilitated early identification and enabled ASP-led optimization of antimicrobial use. These observations highlight the importance of ongoing surveillance of atypical pathogens and the role of stewardship in improving targeted therapy. Disclosures Thomas M. File, Jr., MD, MSc, MACP, FIDSA, Merck: Advisor/Consultant|MicroGenDx: Advisor/Consultant|Paratek: Advisor/Consultant|Shionogi: Advisor/Consultant|Shionogi: Honoraria|ThermoFisher: Advisor/Consultant|ThermoFisher: Honoraria

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2026-01-01
DOI
https://doi.org/10.1093/ofid/ofaf695.894
Primary Topic
Pneumonia and Respiratory Infections
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P-681. Evaluation of Clinical Characteristics and Antimicrobial Stewardship Interventions in Mycoplasma pneumoniae Infections at a Community Teaching Hospital

Paula Politis, File Tm, Matthew R. England, Michael J. Tan
Open Forum Infectious Diseases
Pneumonia and Respiratory Infections
article

P-681. Evaluation of Clinical Characteristics and Antimicrobial Stewardship Interventions in Mycoplasma pneumoniae Infections at a Community Teaching Hospital

Paula Politis, File Tm, Matthew R. England, Michael J. Tan
article en

Abstract

Abstract Background Patients admitted with community-acquired pneumonia (CAP) are empirically treated with broad-spectrum antibiotics due to challenges identifying causative organisms. Mycoplasma pneumoniae is a common atypical pathogen but has historically been difficult to detect. Implementation of rapid molecular diagnostics at our institution improved detection of M. pneumoniae, supporting more targeted interventions by the Antimicrobial Stewardship Program (ASP). A recent rise in M. pneumoniae cases presented an opportunity to assess clinical characteristics, management, and stewardship impact. Methods We performed a retrospective review of patients admitted to our institution from June 2024 – March 2025 with M. pneumoniae identified by PCR, including the Respiratory Pathogen Panel (RPP) and the Pneumonia Panel (PN). Data collected included demographics, comorbidities, imaging, co-infections, antimicrobial therapy, ASP interventions, and outcomes. Results 55 patients were reviewed (median age 46 years, 60% female), with most diagnoses occurring in fall months (September–November). Dyspnea and cough were the most common complaints. Pneumonia was diagnosed in 76% of cases and 19% of those were admitted to the ICU. Potential co-pathogens were observed in 44%, including bacterial (14%), viral (16%), and mixed (13%) cases. Median length of stay was 3 days; mortality was 5.5%. Most patients received azithromycin (47%) or doxycycline (45%). The ASP provided 53 interventions across 29 patients, including 7 in which atypical coverage was initiated. Median procalcitonin and WBC were 0.13 and 10, respectively. Additional results in Tables 1–3. Conclusion A marked rise in M. pneumoniae cases was observed over the review timeframe, consistent with known cyclical trends and potentially influenced by reduced public health mitigation measures following the COVID-19 pandemic. Most infections occurred in younger female patients with typical clinical findings and were managed on general medical floors with short stays. Rapid diagnostic testing facilitated early identification and enabled ASP-led optimization of antimicrobial use. These observations highlight the importance of ongoing surveillance of atypical pathogens and the role of stewardship in improving targeted therapy. Disclosures Thomas M. File, Jr., MD, MSc, MACP, FIDSA, Merck: Advisor/Consultant|MicroGenDx: Advisor/Consultant|Paratek: Advisor/Consultant|Shionogi: Advisor/Consultant|Shionogi: Honoraria|ThermoFisher: Advisor/Consultant|ThermoFisher: Honoraria

Open Forum Infectious DiseasesVol. 13(Supplement_1)
Summa Health System (US)
Good health and well-being
Openalex Percentile: Top 92%
Pneumonia and Respiratory Infections
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.